Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody.[9] The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.[10][11]
The most common side effects include upper respiratory infections, injection site reactions and fungal (tinea) infections.[12]
The drug was developed by Eli Lilly and Co. and is approved for the treatment of plaque psoriasis in the European Union and the United States as of 2016.[6][13]
^"12 Difficult-to-Pronounce Drug Names". Pharmacy Times. 7 February 2018. Archived from the original on 21 March 2018. Retrieved 22 March 2018.
^"Ixekizumab (Taltz) Use During Pregnancy". Drugs.com. 27 November 2019. Retrieved 27 March 2020.
^"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^"Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 21 August 2019. Retrieved 27 March 2020.
^ ab"Taltz EPAR". European Medicines Agency (EMA). 2 May 2016. Retrieved 27 March 2020.
^Cite error: The named reference Vu2016 was invoked but never defined (see the help page).
^Cite error: The named reference Kiwalkar2019 was invoked but never defined (see the help page).
^"Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
^Cite error: The named reference AC was invoked but never defined (see the help page).
^Cai Y, Fleming C, Yan J (July 2013). "Dermal γδ T cells--a new player in the pathogenesis of psoriasis". International Immunopharmacology. 16 (3): 388–391. doi:10.1016/j.intimp.2013.02.018. PMID 23499509.
^Cite error: The named reference FDA PR 20160322 was invoked but never defined (see the help page).
^"Taltz (ixekizumab) Injection". U.S. Food and Drug Administration (FDA). 3 May 2016. Retrieved 27 March 2020.
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized...
IL-17, an important part of the inflammatory system: secukinumab and ixekizumab. They are often considered in cases where TNFi drugs are not effective...
to inhibit TNF-α signaling. Additional monoclonal antibodies, such as ixekizumab, have been developed against pro-inflammatory cytokines and inhibit the...
psoriasis, indirectly affecting Th17 immune response and production of IL-17. Ixekizumab, an IL-17A antagonist, has been reported to have faster onset of action...
Global Information
(what is this?) (verify)